Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Rank in Stocks #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Share Price
$0.03702159
Last synced: 2024-01-29
Market Cap
$7.21M
Change (1 day)
-3.08%
Change (1 year)
0.00%
Country
AU
Trade Antisense Therapeutics Limited (ANP)

Category

Stock price history for Antisense Therapeutics Limited (ANP)
Highest end of day price: $0.04 on 2024-01-01

Lowest end of day price: $0.89 on 2001-12-01
Stock price history of Antisense Therapeutics Limited from 2001 to 2026
Annual Stock Price Performance
Year Performance
2024 3.20%
2023 -37.05%
2022 -56.36%
2021 59.69%
2020 44.65%
2019 191.58%
2018 3.71%
2017 -27.93%
2016 -45.26%
2015 -30.97%
2014 -50.82%
2013 16.96%
2012 -52.56%
2011 252.85%
2010 -78.09%
2009 107.28%
2008 -31.61%
2007 18.43%
2006 15.79%
2005 -72.58%
2004 4.39%
2003 129.21%
2002 -69.82%
2001 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$171.67 -
DE
$161.67 23.26%
DE
$35.97 20.03%
JP
$223.76 36.76%
CH
$20.76 10.90%
IN